Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

An illustration of the Recor renal denervation ablation balloon at work in the renal artery.. Renal Denervation Recor RDN ablation balloon #TCT2021

News | Hypertension

Renal Denervation Combined With Medication Can Treat Resistant Hypertension

November 9, 2021 — Six-month outcomes from the randomized RADIANCE-HTN TRIO Trial comparing endovascular ultrasound ...

November 09, 2021

$Abbott's fractional flow reserve (FFR) system. #TCT #TCT21 #FAME3$

News | FFR Technologies

FAME 3 Study Finds FFR Guided PCI Did Not Perform as Well at One-year Compared to Bypass Surgery

November 9, 2021 — The primary results of the Fractional Flow Reserve Versus Angiography for Multivessel Evaluation ...

November 09, 2021

The Alvimedica Cre8 Evo Cre8 polymer-free amphilimus-eluting stent

News | Stents

Patients With Diabetes Undergoing PCI Have Less Target Lesion Failure With Amphilimus-eluting Stents

November 9, 2021 — Results from SUGAR trial, a randomized, controlled, multicenter trial conducted exclusively in ...

November 09, 2021

TAVR CT image reconstruction of an implanted Medtronic CoreValve. #TCT21 #TCT #TAVR #SURTAVI

News | Heart Valve Technology

Intermediate-risk Patients Have Similar Five-year Outcomes With Transcatheter or Surgical Aortic Valve Replacement

November 9, 2021 — New five-year data from the SURTAVI trial found that there was no difference in all-cause mortality ...

November 09, 2021

A PARTNER 3 trial economic analysis shows for low surgical risk patients, TAVR is cost-saving compared with SAVR. TAVR Sapien Valve visualized using a GE guidance software. #TCT2021

News | Structural Heart

TAVR Is Cost Effective Compared With Surgical Replacement for Low-risk Patients

November 9, 2021 — An economic analysis of data from PARTNER 3, a randomized trial comparing transcatheter aortic valve ...

November 09, 2021

News | FFR Technologies

QFR Technology for Advanced Coronary Artery Disease Leads to Improved Outcomes

November 9, 2021 — Use of a novel technique called the quantitative flow ratio (QFR) to precisely identify and measure ...

November 09, 2021

SARS-CoV-2 (COVID-19) virus added to cells. Image from the Institute for Molecular Bioscience, The University of Queensland. Image of the COVID-19 Virus

News | Coronavirus (COVID-19)

Vascular Disease in COVID-19 is Not Caused by Viral Infection of Blood Vessels

November 9, 2021 — The COVID-19 (SARS-CoV-2) virus does not infect blood vessels, despite the high risk of blood clots ...

November 09, 2021

The Edwards Lifesciences Evoque transcatheter tricuspid valve replacement system demonstrated sustained favorable patient outcomes at six months in the TRISCEND study.

News | Structural Heart

Six-Month Outcomes Positive for Transfemoral Tricuspid Valve in Tricuspid Regurgitation Patients

November 8, 2021 — Results from a clinical trial of the Edwards Lifesciences Evoque transcatheter tricuspid valve ...

November 08, 2021

BioCardia's CardiAMP cell therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure to potentially stimulate the body’s natural healing response. The therapy incorporates a pre-procedural screening assay to identify those patients who are likely responders to the therapy, a first for a cardiac cell therapy.

News | Stem Cell Therapies

BioCardia Announces First Patient Treated in CardiAMP Cell Therapy Trial for Chronic Myocardial Ischemia

October 28, 2021 – The first patient has been treated in a new trial using stem cell therapy to treat chronic myocardial ...

October 28, 2021

The CathVision's novel EP recording technology and amplifier ECGenius used artificial intelligence (AI) confirms if pulmonary vein isolation (PVI) is complete to reduce need for repeat EP ablations procedures.

News | EP Lab

CathVision Announces First Patient Enrollments in PVISION Multicenter Clinical Study

October 28, 2021 — CathVision, a medical technology company developing electrophysiology (EP) solutions in EP recording ...

October 28, 2021

HeartFlow, Inc., a leader in revolutionizing precision heart care, announced the commencement of the REVEALPLAQUE (A pRospEctiVe, multicEnter study to AnaLyze PLAQUE using CCTA) trial to evaluate HeartFlow’s non-invasive plaque technology, an automated, deep learning-based method for identifying, characterizing and segmenting plaque in the coronary arteries

News | Computed Tomography (CT)

HeartFlow Announces Enrollment of First Two Patients in REVEALPLAQUE Trial

October 20, 2021 — HeartFlow Inc. announced the commencement of the REVEALPLAQUE (A pRospEctiVe, multicEnter study to ...

October 20, 2021

The objective of this clinical investigation has been to evaluate safety and performance outcomes of SELUTION SLR, MedAlliance’s novel sirolimus-eluting balloon, for the treatment of long tibial occlusive lesions (TASC C & D) in patients with Critical Limb Ischemia (CLI). It was presented at VIVA 2021.

News | Drug-Eluting Balloons

18-Month Below-the-Knee Data With MedAlliance’s SELUTION SLR Presented at VIVA

October 20, 2021 — 18-month results from the PRESTIGE* Below-the-Knee (BTK) study have been presented as a late-breaking ...

October 20, 2021

the Eluvia stent exhibited superiority with a primary patency rate of 85.4% versus 76.3% with BMS (p=0.0077).1 The analysis also confirmed a significantly greater rate of sustained clinical improvement without reintervention

News | Peripheral Artery Disease (PAD)

Boston Scientific Eluvia Drug-Eluting Vascular Stent System Exhibits Superiority Compared to Bare Metal Stents

October 20, 2021 — Boston Scientific Corporation announced positive data for the Eluvia Drug-Eluting Vascular Stent ...

October 20, 2021

$Cardiac CTA derived left atrium emptying fraction (LAEF) improves predictive performance of established clinical risk scores and may be used to assess TAVR patient risk during pre-procedure workup and post-procedural surveillance. These images show LAVmax (A and B), LAVmin (C and D), and LAEF using cardiac CTA. LAEF was calculated as (LAVmax-LAVmin)/LAVmax x 100. Given LAVmax of 109 mL and LAVmin of 80 mL, the LAEF was calculated to be 27%. Image courtesy of AJR.$

News | Computed Tomography (CT)

Cardiac CTA Parameters Predict Post-TAVR Mortality

October 14, 2021 — Cardiac computed tomography angiography (CTA) derived left atrium emptying fraction (LAEF) improves ...

October 14, 2021

European Society of Cardiology 2021 Late-breaking hot-line Studies presented with links.

News | ESC | By Dave Fornell, DAIC Editor

European Society of Cardiology 2021 Late-breaking Studies

October 4, 2021 — Here are links to all the late-breaking cardiology studies presented in Hot-Line sessions at the 2021 ...

October 04, 2021